Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
| ▸ | F10 | P00742 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 2/20 | 0.33 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.30 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18250727 | 0.92 | — | — | |
| SCHEMBL18250691 | 0.84 | KDM4E (0.38) | F10GRM1ALDH1A1POLBKMT2A | |
| SCHEMBL18250732 | 0.84 | F10 (0.37) | CYP11B2F10ALDH1A1POLBKMT2A | |
| SCHEMBL4964108 | 0.82 | KDM4E (0.40) | F10GRM1KDM4E | |
| SCHEMBL11015922 | 0.82 | KDM4E (0.40) | F10GRM1KDM4E | |
| SCHEMBL7893572 | 0.80 | OPRM1 (0.40) | F10KDM4E | |
| SCHEMBL18322563 | 0.80 | F10 (0.36) | F10ALDH1A1POLBKMT2AKDM4E | |
| SCHEMBL3312030 | 0.79 | MEN1 (0.39) | F10ALDH1A1KMT2A | |
| SCHEMBL18322749 | 0.79 | HCAR1 (0.38) | F10ALDH1A1POLBKMT2AHPGD | |
| SCHEMBL13331620 | 0.77 | F10 (0.34) | F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2976086-B1 | COMBINATION OF CATALYTIC MTORC 1/2 INHIBITORS AND SELECTIVE INHIBITORS OF AURORA A KINASE | MILLENNIUM PHARM INC (US) | 2020-10-14 | — | — | EP | disclosed |
| US-9724354-B2 | Combination of catalytic mTORC1/2 inhibitors and selective inhibitors of Aurora A kinase | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-20170209448-A1 | TREATMENT REGIMENS USING MULTIPLE PHARMACEUTICAL AGENTS | INTELLIKINE LLC | 2017-07-27 | — | — | US | disclosed |
| US-9669032-B2 | Enhanced treatment regimens using mTOR inhibitors | INTELLIKINE LLC (US) | 2017-06-06 | — | — | US | disclosed |
| EP-3153023-A1 | BENZOXAZOLE KINASE INHIBITORS AND METHODS OF USE | Intellikine, LLC (US) | 2017-04-12 | — | — | EP | disclosed |
| US-20160287596-A1 | Benzoxazole Kinase Inhibitors and Methods of Use | FAETH THERAPEUTICS, INC. | 2016-10-06 | — | — | US | disclosed |
| US-20160287597-A1 | Treatment Regimens Using Multiple Pharmaceutical Agents | INTELLIKINE LLC | 2016-10-06 | — | — | US | disclosed |
| US-20160287595-A1 | Combination Pharmaceutical Compositions and Uses Thereof | CALITHERA BIOSCIENCES, INC. | 2016-10-06 | — | — | US | disclosed |
| US-20160271140-A1 | COMBINATION OF CATALYTIC MTORC 1/2 INHIBITORS AND SELECTIVE INHIBITORS OF AURORA A KINASE | MILLENNIUM PHARMACEUTICALS, INC. | 2016-09-22 | — | — | US | disclosed |
| US-20160235758-A1 | COMBINATION OF MTOR INHIBITORS AND PI3-KINASE INHIBITORS, AND USES THEREOF | INTELLIKINE LLC | 2016-08-18 | — | — | US | disclosed |
| US-20140128599-A1 | BENZOXAZOLE KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE LLC (US) | 2014-05-08 | — | — | US | disclosed |
| US-20140030256-A1 | BENZOXAZOLE KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE LLC (US) | 2014-01-30 | — | — | US | disclosed |
| US-20130209543-A1 | ENHANCED TREATMENT REGIMENS USING MTOR INHIBITORS | INTELLIKINE LLC (US) | 2013-08-15 | — | — | US | disclosed |
| US-8476431-B2 | Benzoxazole kinase inhibitors and methods of use | Itellikine LLC (US) | 2013-07-02 | — | — | US | disclosed |
| US-8476282-B2 | Benzoxazole kinase inhibitors and methods of use | INTELLIKINE LLC (US) | 2013-07-02 | — | — | US | disclosed |
| US-8450329-B2 | — | — | 2013-05-28 | — | — | US | disclosed |
| US-8450480-B2 | — | — | 2013-05-28 | — | — | US | disclosed |
| US-20120294930-A1 | COMBINATION OF KINASE INHIBITORS AND USES THEREOF | INTELLIKINE LLC (US) | 2012-11-22 | — | — | US | disclosed |
| US-20100190749-A1 | Benzoxazole kinase inhibitors and methods of use | FAETH THERAPEUTICS, INC. | 2010-07-29 | — | — | US | disclosed |
| US-20100184760-A1 | Benzoxazole kinase inhibitors and methods of use | FAETH THERAPEUTICS, INC. | 2010-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140128599-A1 | BENZOXAZOLE KINASE INHIBITORS AND METHODS OF USE | BMX, MTOR, PDPK1 | CYP11B2 880/4885F10 3449/4885GRM5 993/4885 |
| US-20160287596-A1 | Benzoxazole Kinase Inhibitors and Methods of Use | BMX, MTOR, PDPK1 | CYP11B2 880/4885F10 3449/4885GRM5 993/4885 |
| US-20100184760-A1 | Benzoxazole kinase inhibitors and methods of use | BMX, MTOR, PDPK1 | CYP11B2 880/4885F10 3449/4885GRM5 993/4885 |
| US-20160287595-A1 | Combination Pharmaceutical Compositions and Uses Thereof | CDC25C, CCNC, CDC25B | CYP11B2 277/4885F10 4582/4885GRM5 3764/4885 |
| US-20130209543-A1 | ENHANCED TREATMENT REGIMENS USING MTOR INHIBITORS | RICTOR, MTOR, RPTOR | CYP11B2 1318/4885F10 4481/4885GRM5 1345/4885 |
| US-20140030256-A1 | BENZOXAZOLE KINASE INHIBITORS AND METHODS OF USE | BMX, MTOR, PDPK1 | CYP11B2 880/4885F10 3449/4885GRM5 993/4885 |
| US-20160271140-A1 | COMBINATION OF CATALYTIC MTORC 1/2 INHIBITORS AND SELECTIVE INHIBITORS OF AURORA A KINASE | AURKC, AURKA, AURKB | CYP11B2 2960/4885F10 4562/4885GRM5 4724/4885 |
| US-20160235758-A1 | COMBINATION OF MTOR INHIBITORS AND PI3-KINASE INHIBITORS, AND USES THEREOF | MTOR, RPTOR, RICTOR | CYP11B2 2400/4885F10 4148/4885GRM5 2960/4885 |
| US-20100190749-A1 | Benzoxazole kinase inhibitors and methods of use | BMX, MTOR, PDPK1 | CYP11B2 880/4885F10 3449/4885GRM5 993/4885 |
| US-20170209448-A1 | TREATMENT REGIMENS USING MULTIPLE PHARMACEUTICAL AGENTS | MPL, MTX2, SLC10A1 | CYP11B2 114/4885F10 2976/4885GRM5 978/4885 |
| US-20160287597-A1 | Treatment Regimens Using Multiple Pharmaceutical Agents | MPL, MTX2, SLC10A1 | CYP11B2 114/4885F10 2976/4885GRM5 978/4885 |
| US-20120294930-A1 | COMBINATION OF KINASE INHIBITORS AND USES THEREOF | MTOR, AKT2, MTMR1 | CYP11B2 1406/4885F10 4602/4885GRM5 2461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.